Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD...
Enviro has signed a non-binding LOI regarding licensing of its pyrolysis technology in North America...
Redeye is encouraged by FluoGuide receiving FDA Fast Track Designation for FG001 in High-Grade Gliom...
Fluoguide announced that FG001 has been awarded FDA Fast Track designation, in a major validation of...
Redeye is positive to AAC’s press release today, which states an expected order value of more than E...
Redeye provides an initial comment on BioVica’s Q3 2025/2026 report.
Lower volumes mask an improved earnings profile, as Alcadon benefits from exiting its loss-making Ge...
Seafire enters 2026 with improving earnings momentum, supported by operational initiatives implement...
Redeye comments on Sprint Bioscience's announcement of positive preclinical proof-of-concept data fo...
Redeye briefly comments on Isofol setting the final terms for the exercise of its TO1 warrants issue...
* 300k phones sold annually with +30% GM * Same playbook as Doro: add subscriptions * Price not disc...
Xplora announced today it has agreed to key terms to acquire Emporia Mobile, the second-largest seni...
Redeye attended an analyst meeting with Evolution on Friday and provides its key takeaways from the ...
Fortsatt momentum i den kapitallätta basaffären möter försvarstillväxt.
Investmentbolaget Creades har länge varit synonymt med tillväxt och historisk premievärdering.
Fastator redovisar kraftiga förluster för 2025 på -551 mkr efter nedskrivningar i fastigheter och in...
Redeye provides an initial comment on SciBase's Q4 report, where sales came in somewhat above our es...
Redeye comments on W5’s announcement of the acquisition of KT-Shelter and two potential major orders...
NGM Company Insights: Största bolagen på NGM Kalqyl och FairValue presenterar en samlad genomgång av...
Investors House announced three separate changes today.